Naomi F. Rothfield
#140,968
Most Influential Person Now
Naomi F. Rothfield's AcademicInfluence.com Rankings
Naomi F. Rothfieldphilosophy Degrees
Philosophy
#7355
World Rank
#10559
Historical Rank
Logic
#4413
World Rank
#5702
Historical Rank
Naomi F. Rothfieldbiology Degrees
Biology
#9988
World Rank
#13264
Historical Rank
Immunology
#616
World Rank
#636
Historical Rank
Download Badge
Philosophy Biology
Why Is Naomi F. Rothfield Influential?
(Suggest an Edit or Addition)Naomi F. Rothfield's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The 1982 revised criteria for the classification of systemic lupus erythematosus. (1982) (14503)
- Cyclophosphamide versus placebo in scleroderma lung disease. (2006) (1176)
- Range of antinuclear antibodies in "healthy" individuals. (1997) (779)
- Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma (2004) (548)
- Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. (2007) (418)
- Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen (1987) (384)
- CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate (1992) (357)
- Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. (2002) (311)
- High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. (1986) (301)
- The clinical course of the proliferative and membranous forms of lupus nephritis. (1970) (259)
- cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. (1988) (241)
- Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. (1988) (213)
- Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. (1986) (201)
- Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. (1998) (188)
- A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. (1999) (176)
- Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. (1968) (174)
- Molecular cloning of a human homologue of Drosophila heterochromatin protein HP1 using anti-centromere autoantibodies with anti-chromo specificity. (1993) (173)
- The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. (1967) (170)
- Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. (1978) (165)
- Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. (1991) (162)
- Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. (2005) (153)
- Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials (2016) (149)
- Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. (2004) (149)
- Lupus erythematosus: systemic and cutaneous manifestations. (2006) (148)
- Injection of anticentromere antibodies in interphase disrupts events required for chromosome movement at mitosis (1990) (138)
- Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. (2005) (130)
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. (2009) (129)
- Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. (2001) (127)
- The kinetochore is part of the metaphase chromosome scaffold (1984) (126)
- Prostaglandin E treatment of NZB/NZW mice. (1977) (125)
- Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. (2006) (119)
- Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). (1968) (116)
- Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis. (1977) (114)
- Immunoglobulin class and pattern of nuclear fluorescence in systemic lupus erythematosus. (1966) (111)
- Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. (1989) (110)
- Raised antibody titres to E.B. virus in systemic lupus erythematosus. (1971) (109)
- Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
- MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. (2009) (104)
- Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. (2007) (102)
- Treatment Algorithms in Systemic Lupus Erythematosus (2015) (97)
- Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. (1987) (97)
- Disruption of centromere assembly during interphase inhibits kinetochore morphogenesis and function in mitosis (1991) (95)
- SLOWLY SEDIMENTING MERCAPTOETHANOL-RESISTANT ANTINUCLEAR FACTORS RELATED ANTIGENICALLY TO M IMMUNOGLOBULINS (GAMMA-1M-GLOBULIN) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. (1965) (94)
- A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. (2008) (92)
- RENAL DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS. (1963) (90)
- A long-term longitudinal study of anticentromere antibodies. (1984) (87)
- Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus. (1983) (86)
- Glomerular and dermal depostion of properdin in systemic lupus erythematosus. (1972) (76)
- Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. (2003) (73)
- A comparison of the specificity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. (1984) (70)
- Divergent racial trends in mortality from systemic lupus erythematosus. (1995) (70)
- Corticosteroid treatment in systemic lupus erythematosus. Survival studies. (1977) (66)
- EFFECT OF PREGNANCY ON COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS (1963) (66)
- Outcome measurements in scleroderma: results from a delphi exercise. (2007) (64)
- A Simple Severity of Disease Index for Systemic Lupus Erythematosus (1993) (64)
- Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. (1996) (61)
- The γG subclass of antinuclear and antinucleic acid antibodies (1972) (61)
- Reiter's Syndrome Associated with Campylobacter fetus Infection (1977) (60)
- CHRONIC DISCOID LUPUS ERYTHEMATOSUS. (1963) (59)
- A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. (2003) (59)
- Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus. (1976) (57)
- Isoniazid induction of antinuclear antibodies. A prospective study. (1978) (57)
- A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. (2002) (55)
- The efficacy of antimalarials in systemic lupus erythematosus. (1988) (55)
- Extensive calcinosis cutis with systemic lupus erythematosus. (1990) (54)
- Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. (1997) (53)
- Detection of anticentromere antibodies using cloned autoantigen CENP-B. (1987) (52)
- Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. (1990) (51)
- Immunoglobulin M autoantibody to vimentin intermediate filaments. (1982) (50)
- Primary antiphospholipid syndrome evolving into systemic lupus erythematosus (1996) (50)
- Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. (1990) (49)
- Family Study of Systemic Lupus Erythematosus (1977) (49)
- Association of anti-topoisomerase I with cancer. (1992) (48)
- Relation of positive L.E.-cell preparations to activity of lupus erythematosus and corticosteroid therapy. (1962) (46)
- Role of the centromere/kinetochore in cell cycle control. (1991) (44)
- The response of cultured lymphocytes from patients with systemic lupus erythematosus to DNA. (1967) (41)
- Patterns of nuclear fluorescence and DNA-binding activity. (1973) (41)
- Systemic lupus erythematosus in the younger patient: survival studies. (1980) (41)
- Systemic Lupus Erythematosus; Management During Pregnancy (1978) (41)
- Aseptic necrosis presenting as wrist pain in SLE. (1977) (40)
- The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies. (1990) (40)
- The role of antinuclear reactions in the diagnosis of systemic lupus erythematosus: a study of 53 cases. (1961) (40)
- Clinical and laboratory aspects of raised virus antibody titres in systemic lupus erythematosus. (1973) (40)
- A comparison of the sensitivity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. (1984) (39)
- Longitudinal study of anticentromere and antitopoisomerase-I isotypes. (1995) (38)
- Human autoantibody to topoisomerase II. (1989) (37)
- Efficacy of antimalarials in systemic lupus erythematosus. (1988) (34)
- Immune-complex nephritis in bacterial endocarditis. (1976) (34)
- The clinical utility of the lupus band test. (1984) (34)
- Hypomorphic variant of C3, arthritis, and chronic glomerulonephritis. (1978) (32)
- A Mini-Epidemic of Goodpasture’s Syndrome (1974) (32)
- Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. (2004) (31)
- Familial partial deficiency of the third component of complement (C3) and the hypocomplementemic cutaneous vasculitis syndrome. (1980) (30)
- An evaluation of the preliminary criteria for the diagnosis of systemic lupus erythematosus. (1972) (29)
- Chiasmal Herniation as a Complication of Bromocriptine Therapy (1996) (29)
- Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients (2013) (26)
- Systemic lupus erythematosus. (1982) (26)
- Selective complete Clq deficiency associated with systemic lupus erythematosus. (1983) (25)
- The coexistence of rheumatoid arthritis and systemic lupus erythematosus: a case report and review of the literature. (1981) (25)
- Nasal septal perforation in systemic lupus erythematosus. (1974) (24)
- Progression of Esophageal Dysmotility in Systemic Sclerosis (2012) (23)
- Clinical and serologic significance of cutaneous deposits of immunoglobulins, C3, and C1q in SLE patients with nephritis. (1978) (23)
- Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up (2017) (23)
- Racial aspects of comorbidity in systemic lupus erythematosus. (1996) (22)
- An epidemiologic study of households exposed to canine systemic lupus erythematosus. (1980) (22)
- Clinical features and serologic abnormalities in juvenile rheumatoid arthritis. (1974) (22)
- Clinical significance of antinuclear antibodies. (1967) (20)
- Clinical aspects and treatment of systemic lupus erythematosus. (1989) (18)
- Autoantibodies in systemic sclerosis. (1995) (18)
- Prostaglandine1 treatment of NZB/NZWF1 hybrid MICE (1977) (18)
- Studies of repeat skin biopsies of nonlesional skin in patients with systemic lupus erythematosus. (1982) (17)
- A mini-epidemic of Goodpasture's syndrome clinical and immunological studies. (1974) (16)
- Analysis of human antitopoisomerase-I idiotypes. (1993) (15)
- Bullae in systemic lupus erythematosus. (1961) (15)
- Antibodies to topoisomerase I in sera from patients with scleroderma. (1987) (15)
- Systemic lupus erythematosus. (1969) (14)
- Demonstration of beta 1H globulin together with C3 in the dermal-epidermal junction of patients with systemic lupus erythematosus. (1979) (13)
- Partial H (beta 1H) deficiency and glomerulonephritis in two families. (1982) (12)
- Isotype analysis of the anti-CENP-B anticentromere autoantibody: evidence for restricted clonality. (1989) (12)
- THE IMMUNOPATHOLOGY OF LUPUS ERYTHEMATOSUS. * (1960) (11)
- Pathways of complement activation in chronic discoid lupus: serologic and immunofluorescence studies. (1977) (11)
- The gammaG subclass of antinuclear and antinucleic acid antibodies. (1972) (10)
- Migration of centromere proteins in rabbit spermatids (1992) (10)
- Survival in Systemic Lupus Erythematosus-Reply (1978) (9)
- Editorials: Immunosuppressive therapy in lupus erythematosus. (1975) (9)
- HETEROZYGOUS C3 DEFICIENCY ASSOCIATED WITH A SYSTEMIC LUPUS ERYTHEMATOSUS-LIKE DISEASE (1977) (8)
- Family study of systemic lupus erythematosus: analysis of the clinical history, skin immunofluorescence, and serologic parameters. (1977) (8)
- Congenital heart block, systemic lupus erythematosus, and anti-Ro antibodies. (1985) (8)
- MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon (2008) (7)
- Familial discoid lupus erythematosus associated with heterozygote C2 deficiency. (1980) (7)
- E.B. virus and other viral antibodies in systemic lupus erythematosus. (1973) (6)
- Normal complement in early poststreptococcal glomerulonephritis. (1977) (6)
- Kidney in lupus erythematosus. (1977) (6)
- Systemic lupus erythematosus evolving into rheumatoid arthritis. (2006) (6)
- Multipurpose arthritis centers (1988) (6)
- Idiotypic analysis of human anti-topoisomerase I autoantibodies. (1991) (5)
- Electro-immunoassay for properdin. A comparison with the radioimmunoassay. (1976) (5)
- Autoantibodies in scleroderma. (1992) (5)
- Autoantibodies to scleroderma-associated antigens (1996) (4)
- Osteonecrosis in SLE (2012) (4)
- Topoisomerase-I (Scl-70) Autoantibodies (1996) (3)
- Idiotypic analysis of human anticentromere autoantibodies. (1991) (3)
- The diagnostic features of SLE. (1989) (2)
- Comparison of responders and non-responders to MQX-503, a novel investigational topical nitroglycerin formulation, in treatment of scieroderma-related and non-scleroderma-related Raynaud'S phenomenon (2008) (2)
- Lack of induction of antinuclear antibodies by D-penicillamine in rheumatoid arthritis: a controlled study. (1986) (2)
- Serologic tests in rheumatic diseases. (1969) (2)
- Diagnosis of lupus erythematosus and rheumatoid arthritis in children. (1971) (2)
- Serum antinuclear antibodies in rheumatoid arthritis. (1970) (2)
- Multipurpose arthritis centers. A ten-year progress report. (1988) (2)
- BRAIN NATRIURETIC PEPTIDE LEVELS CORRELATE WITH SIX MINUTE WALK DISTANCE AND WORLD HEALTH ORGANIZATION FUNCTIONAL CLASSIFICATION IN PATENTS WITH CONNECTIVE TISSUE DISEASE -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (2005) (1)
- The present status of antinuclear antibody serology. (1969) (1)
- Book Review Oxford Textbook of Rheumatology Edited by P.J. Maddison, David A. Isenberg, Patricia Woo, and David N. Glass. 1142 pp., illustrated. New York, Oxford University Press, 1993. $210. 0-19-262026-6 (1994) (1)
- Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud's phenomenon (2008) (1)
- General considerations in the treatment of systemic lupus erythematosus. (1969) (1)
- Comment on the article by Lockshin. (1990) (1)
- Molecular cloning and characterization of human centromeric autoantigen CENP-C: a component of the inner kinetochore plate (1993) (1)
- Clinical and serologic significance of cutaneous deposits in systemic lupus erythematosus. (1980) (1)
- Reiter's syndrome associated with champylobacter fetus infection. (1977) (0)
- Comment on the article by Lockshin. Author reply (1990) (0)
- Spontaneous production of autoantibodies to dna in ascitic fluids of (nzb/nzw)f1 (b/w) mice. Abstr. (1981) (0)
- THE 1964 ANNUAL MEETING OF THE AMERICAN RHEUMATISM ASSOCIATION. (1964) (0)
- Isoniazid Induction of Antinuclear Antibodies (2020) (0)
- Letter to the Editor (1969) (0)
- Systemic lupus erythematosus. Laboratory studies. (1977) (0)
- Reply (2016) (0)
- 1088 HYPOMORPHIC VARIANT OF THE FAST C3 ALLELE, GLOMERULO-NEPHRITIS AND ARTHRITIS (1978) (0)
- SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDHOOD (1968) (0)
- Immunoglobulin M Autoantibody to Vimentin (1982) (0)
- Hydroxychloroquine treatment in SLE. (2015) (0)
- Incidence of Anti-Nuclear Antibodies Among First-Degree Relatives of Patients with Chronic Discoid Lupus, Systemic Lupus and Normal Subjects (1968) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Naomi F. Rothfield?
Naomi F. Rothfield is affiliated with the following schools:
